Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Non Operating Income (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Non Operating Income readings, the most recent being $447000.0 for Q1 2026.

  • Quarterly Non Operating Income rose 0.9% to $447000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Mar 2026, up 61.87% year-over-year, with the annual reading at $1.7 million for FY2025, 26.82% down from the prior year.
  • Non Operating Income hit $447000.0 in Q1 2026 for DiaMedica Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.7 million in Q4 2025 and bottomed at -$21000.0 in Q3 2025.
  • Average Non Operating Income over 5 years is $399647.1, with a median of $314000.0 recorded in 2025.
  • The largest annual shift saw Non Operating Income soared 3171.43% in 2022 before it tumbled 950.0% in 2025.
  • DiaMedica Therapeutics' Non Operating Income stood at $229000.0 in 2022, then skyrocketed by 209.61% to $709000.0 in 2023, then decreased by 25.53% to $528000.0 in 2024, then skyrocketed by 218.18% to $1.7 million in 2025, then tumbled by 73.39% to $447000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Non Operating Income are $447000.0 (Q1 2026), $1.7 million (Q4 2025), and -$21000.0 (Q3 2025).